Compounds > 6-heptyne-2,5-diamine
Page last updated: 2024-12-07

6-heptyne-2,5-diamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-heptyne-2,5-diamine: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122175
SCHEMBL ID4808395
MeSH IDM0118529

Synonyms (12)

Synonym
6-heptyne-2,5-diamine
(2r,5r)-hept-6-yne-2,5-diamine
mdl 72175
methyl-acetylenicputrescine
delta-methyl-alpha acetylene putrescine
8-methyl-8-acetylenic putrescine
81645-70-7
hept-6-yne-2,5-diamine
AKOS006338563
SCHEMBL4808395
DTXSID801002114
maputrescine hydrochloride

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"6 mumol after dosing with 1500 mg/day for 4 weeks, the levels after each treatment schedule being sufficient to inhibit ODC as demonstrated by increases in the urinary excretion of decarboxylated S-adenosylmethionine (dc-SAM)."( Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis.
Cornbleet, MA; Haegele, KD; Joder-Ohlenbusch, AM; Kingsnorth, A; Smyth, JF; Tell, GP, 1989)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (72.41)18.7374
1990's8 (27.59)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.87 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
putrescine
[no description available]		3.4780alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		2.8840polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		3.0750polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		1.9710isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		1.9710acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		4.11160alpha-amino acid;
fluoroamino acid		trypanocidal drug
hydroxyurea
[no description available]		1.9810one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		1.9910aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		1.9810alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
ornithine
Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.		7.8840non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		1.9810taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		1.9710beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
n-butyl-1,3-diaminopropane
N-butyl-1,3-diaminopropane: RN given refers to parent cpd		1.9910
n(1),n(8)-diethylspermidine
N(1),N(8)-diethylspermidine: regulator of ornithine decarboxylase		1.9610
s-adenosyl-3-methylthiopropylamine
S-adenosyl-3-methylthiopropylamine: decarboxylated S-adenosylmethionine		2.6630adenosines;
sulfonium compound		Escherichia coli metabolite;
human urinary metabolite;
mouse metabolite;
rat metabolite
mitoguazone
Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.		2.3720guanidines;
hydrazone		antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
2-(fluoromethyl)dehydroornithine methyl ester
[no description available]		2.6630
ethylglyoxal bis(guanylhydrazone)
ethylglyoxal bis(guanylhydrazone): RN given refers to parent cpd		1.9710
mdl 73811
MDL 73811: structure given in first source; RN given refers to (Z)-isomer		1.9910
s-adenosylmethionine
(R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.		3.0650organic cation;
sulfonium compound		coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		03.0650
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.3820
Experimental Hepatoma
[description not available]		02.6530
Cancer of Lung
[description not available]		02.3720
Experimental Neoplasms
[description not available]		01.9610
Experimental Mammary Neoplasms
[description not available]		01.9610
Lung Neoplasms
Tumors or cancer of the LUNG.		02.3720
Cancer of Ovary
[description not available]		01.9910
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		01.9910
Breast Cancer
[description not available]		0210
Cancer of Prostate
[description not available]		02.3820
Cancer of the Thyroid
[description not available]		0210
Breast Neoplasms
Tumors or cancer of the human BREAST.		0210
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.3820
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		0210
B16 Melanoma
[description not available]		01.9710
Polyarthritis
[description not available]		01.9710
Autoimmune Disease
[description not available]		01.9710
Arthritis
Acute or chronic inflammation of JOINTS.		01.9710
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		01.9710
Benign Neoplasms, Brain
[description not available]		01.9710
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		01.9710
Benign Neoplasms
[description not available]		01.9710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9710
Acute Myelogenous Leukemia
[description not available]		01.9710
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		01.9710
Leukemia, Lymphocytic
[description not available]		01.9610
Leukemia L5178
An experimental lymphocytic leukemia of mice.		01.9610
Leukemia, Lymphoid
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.		01.9610
Adenocarcinoma, Basal Cell
[description not available]		01.9710
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9710
Libman-Sacks Disease
[description not available]		01.9710
Lymphatic Diseases
Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.		01.9710
Enlarged Spleen
[description not available]		01.9710
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.		01.9710